Delisting riskPopularity #4,593
GeoVax Labs (GOVX)
Clinical developer of an mpox/smallpox vaccine and gene-directed therapy for head-and-neck cancer.
$0.3699
vs last close+0.01 (+1.82%)
Something off on this page? Send us feedback.
Next report
Nov 12, 26
in 50 days
EPS estimate
−$1.09
Revenue estimate
—
Fiscal quarter
Q3 FY26
EPSReportedEstimate
Mar '25May '25Jul '25Nov '25Apr '26May '26Jul '26Nov '26
Reported−$7.50−$11.25−$8.75−$7.75−$2.29−$2.62−$0.97Pending
Estimate−$19.75−$14.75−$8.69−$5.85−$4.71−$1.60−$2.16−$1.09
Surprise+62.0%+23.7%−0.7%−32.4%+51.3%−63.7%+55.1%—
RevenueReportedEstimate
Mar '25May '25Jul '25Nov '25Apr '26May '26Jul '26Nov '26
Reported$882.5K$1.6M$876.2K————Pending
Estimate$3.0M$1.7M$776.1K$1.0M$1.0M———
Surprise−70.3%−2.9%+12.9%—————
HistoryUpcoming
| Date / Period | Estimate | Reported | Surprise |
|---|---|---|---|
| Dec 2028 | −$0.18 | — | — |
| Sep 2028 | −$0.18 | — | — |
| Jun 2028 | −$0.18 | — | — |
| Mar 2028 | −$0.17 | — | — |
| Dec 2027 | −$0.68 | — | — |
| Sep 2027 | −$0.67 | — | — |
| Jun 2027 | −$0.66 | — | — |
| Mar 2027 | −$0.63 | — | — |
| Dec 2026 | −$1.20 | — | — |
| Nov 2026 | −$1.09 | — | — |
| Jul 2026 | −$2.16 | −$0.97 | +55.1% |
| May 2026 | −$1.60 | −$2.62 | −63.7% |
| Apr 2026 | −$4.71 | −$2.29 | +51.3% |
| Nov 2025 | −$5.85 | −$7.75 | −32.4% |
| Jul 2025 | |||
| May 2025 | |||
| Mar 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Feb 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Mar 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| Apr 2022 | |||
| Mar 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Mar 2021 | |||
| Nov 2020 | |||
| Aug 2020 | |||
| May 2020 | |||
| Dec 2019 | |||
| Nov 2019 | |||
| Aug 2019 | |||
| May 2019 | |||
| Mar 2019 | |||
| Nov 2018 | |||
| Aug 2018 | |||
| May 2018 | |||
| Mar 2018 | |||
| Nov 2017 | |||
| Aug 2017 | |||
| May 2017 | |||
| Mar 2017 | |||
| Nov 2016 | |||
| Aug 2016 | |||
| May 2016 | |||
| Mar 2016 | |||
| Nov 2015 | |||
| Aug 2015 |
| Date / Period | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Dec 2028 | −$0.18 | — | — | $227.5K | — | — | — |
| Sep 2028 | −$0.18 | — | — | $203.1K | — | — | — |
| Jun 2028 | −$0.18 | — | — | $195.0K | — | — | — |
| Mar 2028 | −$0.17 | — | — | $186.9K | — | — | — |
| Dec 2027 | −$0.68 | — | — | $505.5M | — | — | — |
| Sep 2027 | −$0.67 | — | — | $4.9M | — | — | — |
| Jun 2027 | −$0.66 | — | — | $4.7M | — | — | — |
| Mar 2027 | −$0.63 | — | — | $4.5M | — | — | — |
| Dec 2026 | −$1.20 | — | — | $0 | — | — | — |
| Nov 12, 2026 | −$1.09 | — | — | $0 | — | — | — |
| Jul 27, 2026 | −$2.16 | −$0.97 | +55.1% | — | — | — | +3.9% |
| May 14, 2026 | −$1.60 | −$2.62 | −63.7% | — | — | — | −2.4% |
| Apr 2, 2026 | −$4.71 | −$2.29 | +51.3% | $1.0M | — | — | −6.0% |
| Nov 13, 2025 | −$5.85 | −$7.75 | −32.4% | $1.0M | — | — | −3.8% |
| Jul 28, 2025 | |||||||
| May 1, 2025 | |||||||
| Mar 27, 2025 | |||||||
| Nov 12, 2024 | |||||||
| Aug 6, 2024 | |||||||
| May 14, 2024 | |||||||
| Feb 29, 2024 | |||||||
| Nov 8, 2023 | |||||||
| Aug 9, 2023 | |||||||
| May 4, 2023 | |||||||
| Mar 23, 2023 | |||||||
| Nov 9, 2022 | |||||||
| Aug 3, 2022 | |||||||
| Apr 27, 2022 | |||||||
| Mar 9, 2022 | |||||||
| Nov 11, 2021 | |||||||
| Aug 11, 2021 | |||||||
| May 6, 2021 | |||||||
| Mar 23, 2021 | |||||||
| Nov 5, 2020 | |||||||
| Aug 10, 2020 | |||||||
| May 5, 2020 | |||||||
| Dec 31, 2019 | |||||||
| Nov 7, 2019 | |||||||
| Aug 14, 2019 | |||||||
| May 13, 2019 | |||||||
| Mar 27, 2019 | |||||||
| Nov 8, 2018 | |||||||
| Aug 7, 2018 | |||||||
| May 3, 2018 | |||||||
| Mar 23, 2018 | |||||||
| Nov 9, 2017 | |||||||
| Aug 7, 2017 | |||||||
| May 8, 2017 | |||||||
| Mar 24, 2017 | |||||||
| Nov 11, 2016 | |||||||
| Aug 5, 2016 | |||||||
| May 4, 2016 | |||||||
| Mar 16, 2016 | |||||||
| Nov 12, 2015 | |||||||
| Aug 4, 2015 |